Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

11 evidence topics · 5 sources

Summary
  • Guideline sequence: The 2025 AHA/ACC guideline starts drug treatment of resistant hypertension with an ACE inhibitor or ARB, a calcium channel blocker, and a diuretic, then adds spironolactone (25 to 50 mg/day) as the fourth drug. Amiloride (10 to 20 mg) is the alternative when spironolactone or eplerenone is not tolerated, followed by beta-blockers, alpha blockers, central sympatholytic drugs, direct vasodilators, or aprocitentan. Renal denervation is reserved for adults with intolerable side effects to optimal drug regimens. ICER summarizes the guideline as recommending referral to a specialist for a known or suspected secondary cause or when blood pressure remains uncontrolled after more than 6 months of treatment.
  • Anticipated use: Mineralys submitted the NDA for the treatment of hypertension in combination with other antihypertensive drugs, the same wording as the first part of the BAXFENDY (baxdrostat) indication, which adds adults not adequately controlled on other agents. Mineralys describes its target as third-line or later treatment, with resistant hypertension as the initial segment and a “beachhead at fourth line”. Manufacturers told ICER that they view aldosterone synthase inhibitors as appropriate for third- or fourth-line therapy regardless of whether a third first-line agent had been tried.
  • ICER populations and clinical input: ICER assessed three populations: resistant hypertension not at goal; blood pressure above goal on two drugs with intolerance of a third first-line agent; and blood pressure above goal on two drugs without a trial of a third first-line agent. ICER consulted five clinical experts (two internists, two cardiologists, one nephrologist), who identified mineralocorticoid receptor antagonists such as spironolactone as the preferred option for people who remain uncontrolled despite regular medication use.
  • Care setting: Lorundrostat is orally administered. Mineralys estimates about 60,000 physicians write half of the third-line or later prescriptions, with a 60/40 split between primary care and specialists, most of whom are cardiologists. The guideline assigns routine and complex hypertension care to primary care physicians and cardiologists, and complex care involving secondary causes or resistant hypertension to nephrologists, endocrinologists, and hypertension specialists.